Metadon Dne (Methadone Hydrochloride)

Methadone is a full agonist at the mu‑opioid receptor. By binding to this receptor, it activates the same pathways as other opioids, producing analgesia and suppressing the neural mechanisms that cause withdrawal, while its long half‑life allows stable blood levels with once‑daily dosing.

The appropriate dose of Metadon Dne is determined individually by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosage adjustments are made under medical supervision to ensure safety and effectiveness.

Safety data for methadone use in pregnancy and lactation are limited. It may be prescribed when the benefits outweigh potential risks, but clinicians should evaluate each case carefully and monitor both mother and infant closely.

To order Metadon Dne, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both methadone (Metadon Dne) and buprenorphine are used for opioid dependence, but methadone is a full mu‑opioid agonist with a longer half‑life, offering more consistent plasma levels, while buprenorphine is a partial agonist with a ceiling effect on respiratory depression, which may reduce overdose risk.

Metadon Dne should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain potency and stability.

Metadon Dne is taken orally, usually as a tablet, and should be swallowed whole with water. The exact dosing schedule is set by the prescribing clinician and may be adjusted based on therapeutic response and tolerability.

Serious risks include respiratory depression, especially when combined with other CNS depressants, and cardiac complications such as QT interval prolongation that can lead to torsades de pointes. Patients should be monitored for signs of severe sedation, breathing difficulties, or irregular heart rhythms.

Metadon Dne is contraindicated in individuals with known hypersensitivity to methadone, those taking monoamine oxidase inhibitors, or patients with significant uncontrolled cardiac arrhythmias. Caution is also advised for patients with severe respiratory disease, liver impairment, or a history of substance misuse without proper supervision.